Citing “fantastic opportunity,” FDA and EMA call for rigorous science. Agency scientists tell FTD Treatment Study Group: Explore individualized outcomes, and connect biomarkers to meaningful improvement.
Hoping for better luck in clinical trials than their Alzheimer’s colleagues had in the past decade, FTD researchers are now chasing biomarkers. It’s slim pickings so far, but neurofilament, tau PET, and MRI are showing promise.
At a workshop of the Frontotemporal Dementia Treatment Study Group, advocates and regulatory scientists urged leaders from industry and academia to forge a collaborative approach while the field is still young.
A bit less strapped for funding, researchers are considering the next steps for Lewy body, frontotemporal, and vascular dementia.
NAPA's latest collective exercise was a conference to update the field on progress in the past three years and advise the NIH on how to spend the next round of funds.
At Athens meeting, scientists had new data on where these species appear in the brain, how they disrupt neurons, and whether oligo-specific antibodies would work.
Results raise the tentative prospect that a medical food might have possible cognitive benefit early in disease.
AV1451 appears too weak to diagnose non-AD tauopathies.
Preliminary data suggests a long lag between Aβ and tau deposits as the disease develops.
Using PET, researchers are trying to match tau spread against structural and functional defects.
The prion concept continues to infiltrate the neurodegeneration field, with models of SOD1 propagation and a bevy of tau strains.
The drug benefits some patients with mild amyotrophic lateral sclerosis, and is approved in Japan.
When clinicians and pathologists argue, sometimes genetics can settle the dispute. How about DLB?
How α-synuclein aggregates spread, quite possibly starting in the nose in some people, sets DLB apart from its better-known cousins, Alzheimer’s and Parkinson’s.
In dementia with Lewy bodies, basic scans are used in routine diagnosis. Multimodal imaging and new PET tracers for affected neurotransmitters of pathological deposits in the brain and gut are entering research settings.